Avita Medical (NASDAQ:RCEL) mentioned Wednesday that its preliminary business income for the third quarter was $13.5 million, up 50% from final yr.
The preliminary gross margin for Q3 was about 84.5%.
The forecast for full-year 2023 business income stays unchanged within the vary of $51 to $53 million.
The corporate mentioned it additionally closed a debt financing facility for as much as $90 million with OrbiMed, a healthcare funding agency, for monetary flexibility to help portfolio growth and world initiatives, amongst different issues.
Press Launch.
Shares -3.8% at $10.22.
